Macroglobulinemia disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: MCR004 MIFTS: 53	Macroglobulinemia Categories: Metabolic diseases
Genes Tissues Related diseases Publications Pathways Drugs Download Expand all tables

Sources

Aliases & Classifications for Macroglobulinemia

MalaCards integrated aliases for Macroglobulinemia:

Name: Macroglobulinemia ¹² ⁷⁶ ¹⁵

Waldenstrom Macroglobulinemia ⁷³

Primary Macroglobulinemia ¹²

Classifications:

MalaCards categories:
Global: Metabolic diseases

See all MalaCards categories (disease lists)

ICD10: ³³

Neoplasms

Malignant neoplasms, stated or presumed to be primary, of lymphoid, haematopoietic and related tissue

Malignant immunoproliferative diseases

Waldenstr

External Ids:

Disease Ontology ¹² DOID:9080

ICD10 ³³ C88.0

ICD9CM ³⁵ 273.3

MeSH ⁴⁴ D008258

NCIt ⁵⁰ C115212 C80307

SNOMED-CT ⁶⁸ 109981009 154750002 190014001 more

UMLS ⁷³ C0024419 C2936755

Sources

Summaries for Macroglobulinemia

MalaCards based summary : Macroglobulinemia, also known as waldenstrom macroglobulinemia, is related to waldenstrom macroglobulinemia and lymphoplasmacytic lymphoma. An important gene associated with Macroglobulinemia is MYD88 (Myeloid Differentiation Primary Response 88), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs rituximab and Lenograstim have been mentioned in the context of this disorder. Affiliated tissues include b cells, bone and bone marrow, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

Wikipedia : ⁷⁶ Macroglobulinemia is the presence of increased levels of macroglobulins in the circulating blood. It is... more...

Sources

Related Diseases for Macroglobulinemia

Diseases related to Macroglobulinemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 213)

#	Related Disease	Score	Top Affiliating Genes
1	waldenstrom macroglobulinemia	33.9	CD40LG CXCR4 MYD88 PAX5
2	lymphoplasmacytic lymphoma	32.1	CD40LG CXCL12 CXCR4 MYD88 PAX5
3	b-cell lymphomas	30.4	BTK PAX5 TNFSF13B
4	heavy chain disease	30.4	CD40LG MYD88
5	cryoglobulinemia	30.0	CD27 CD40LG TNFSF13B
6	whim syndrome	29.8	CXCL12 CXCR4
7	agammaglobulinemia	29.7	BTK CD40LG CXCL12
8	mantle cell lymphoma	29.4	AKT1 BTK CD40LG PAX5
9	hematologic cancer	28.9	CD40LG CXCL12 CXCR4 PAX5
10	myeloma, multiple	28.8	AKT1 CD40LG CXCL12 CXCR4 IL6 TNFSF13B
11	autoimmune disease	28.3	CD40LG IL6 TNFRSF13B TNFSF13B
12	leukemia, chronic lymphocytic	27.3	CD27 CD40LG CD70 CXCL12 CXCR4 PAX5
13	lymphoma, non-hodgkin, familial	26.3	CD27 CD40LG CXCL12 CXCR4 PAX5 TNFRSF13B
14	macroglobulinemia, waldenstrom 1	12.2
15	waldenstroem's macroglobulinemia	12.0
16	macroglobulinemia, waldenstrom 2	12.0
17	schnitzler syndrome	11.4
18	monoclonal gammopathy of uncertain significance	11.3
19	light chain deposition disease	11.2
20	immunoglobulin a deficiency 1	10.7	BTK CD40LG
21	immunodeficiency with hyper-igm, type 4	10.7	CD40LG TNFSF13B
22	congenital hypogammaglobulinemia	10.7	BTK CD40LG
23	polyclonal hypergammaglobulinemia	10.7	CD40LG IL6
24	immunodeficiency with hyper-igm, type 1	10.6	BTK CD40LG
25	ascaris lumbricoides infection	10.6	IL6 TNFSF13B
26	transient arthritis	10.5	CD40LG IL6
27	central nervous system vasculitis	10.5	CD40LG IL6
28	osteosclerotic myeloma	10.5	CD40LG IL6
29	lymphoma	10.5
30	intussusception	10.5	CD40LG IL6
31	salivary gland disease	10.4	CD40LG TNFSF13B
32	toxoplasmosis	10.4	CD40LG IL6 MYD88
33	aids dementia complex	10.4	CXCL12 CXCR4
34	viral infectious disease	10.4	CD40LG CXCR4 IL6
35	hypersensitivity reaction disease	10.3	CD40LG IL6 TNFSF13B
36	immune system disease	10.3	CD40LG IL6 TNFSF13B
37	non-secretory myeloma	10.3	CD40LG ITGAE
38	hypersensitivity reaction type iii disease	10.3	CD40LG IL6
39	primary effusion lymphoma	10.3	AKT1 IL6
40	multicentric castleman disease	10.3	IL6 PAX5
41	connective tissue disease	10.3	CD40LG IL6 TNFSF13B
42	gamma heavy chain disease	10.2	CD40LG MYD88
43	plasma protein metabolism disease	10.2	BTK CD40LG CXCR4 MYD88
44	leukemia	10.2
45	primary central nervous system lymphoma	10.1	CXCL12 MYD88 PAX5
46	amyloidosis	10.1
47	intraocular lymphoma	10.1	CXCL12 CXCR4 PAX5
48	lymph node disease	10.1	CD40LG IL6 ITGAE
49	monoclonal paraproteinemia	10.1	CD27 CD40LG MYD88
50	neuropathy	10.0

Graphical network of the top 20 diseases related to Macroglobulinemia:

Sources

Symptoms & Phenotypes for Macroglobulinemia

GenomeRNAi Phenotypes related to Macroglobulinemia according to GeneCards Suite gene sharing:

²⁶

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	Synthetic lethal with MLN4924 (a NAE inhibitor)	GR00250-A-1	9.4	MYD88 AKT1 CD40LG CD70 CXCR4
2	Synthetic lethal with MLN4924 (a NAE inhibitor)	GR00250-A-2	9.4	MYD88 AKT1 BTK CD27 CD40LG CD70

MGI Mouse Phenotypes related to Macroglobulinemia:

⁴⁶

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	hematopoietic system	MP:0005397	9.97	PAX5 TNFRSF13B TNFSF13B AKT1 BTK CD27
2	cellular	MP:0005384	9.91	CXCR4 IL6 MYD88 PAX5 AKT1 BTK
3	immune system	MP:0005387	9.77	AKT1 BTK CD27 CD40LG CD70 CXCL12
4	neoplasm	MP:0002006	9.17	AKT1 BTK CXCR4 IL6 MYD88 PAX5

Sources

Drugs & Therapeutics for Macroglobulinemia

Drugs for Macroglobulinemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 374)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

rituximab

Approved

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

174722-31-7

10201696

Lenograstim

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable

135968-09-1

Etoposide

Approved

Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable

33419-42-0

36462

Methotrexate

Approved

Phase 4,Phase 2,Phase 1,Not Applicable

1959-05-2, 59-05-2

126941

Cytarabine

Approved, Investigational

Phase 4,Phase 2,Phase 1,Not Applicable

147-94-4

6253

Thiotepa

Approved, Investigational

Phase 4,Phase 2,Phase 3,Not Applicable

52-24-4

5453

Cyclophosphamide

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable

50-18-0, 6055-19-2

2907

Dexamethasone

Approved, Investigational, Vet_approved

Phase 4,Phase 3,Phase 2,Phase 1

50-02-2

5743

Bortezomib

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

179324-69-7

387447 93860

Prednisolone

Approved, Vet_approved

Phase 4,Phase 2,Phase 1,Not Applicable

50-24-8

5755

Methylprednisolone

Approved, Vet_approved

Phase 4,Phase 2,Phase 1,Not Applicable

83-43-2

6741

Prednisone

Approved, Vet_approved

Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1

53-03-2

5865

leucovorin

Approved, Nutraceutical

Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1

58-05-9

143 6006

Folic Acid

Approved, Nutraceutical, Vet_approved

Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1

59-30-3

6037

Dexamethasone acetate

Phase 4,Phase 3,Phase 2,Phase 1

1177-87-3

Alkylating Agents

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

glucocorticoids

Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable

protease inhibitors

Phase 4,Phase 3,Phase 2,Phase 1

Folic Acid Antagonists

Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1

Gastrointestinal Agents

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

HIV Protease Inhibitors

Phase 4,Phase 3,Phase 2,Phase 1

Hormone Antagonists

Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable

Dermatologic Agents

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Nucleic Acid Synthesis Inhibitors

Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1

Hormones

Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable

Hormones, Hormone Substitutes, and Hormone Antagonists

Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable

Peripheral Nervous System Agents

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Anti-Bacterial Agents

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Vitamin B Complex

Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1

Antibodies

Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1

Immunoglobulins

Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1

Etoposide phosphate

Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable

Immunosuppressive Agents

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Anti-Infective Agents

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Antiemetics

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Protective Agents

Phase 4,Phase 2,Phase 1,Not Applicable

Anti-Inflammatory Agents

Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable

Antilymphocyte Serum

Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable

Antirheumatic Agents

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

BB 1101

Phase 4,Phase 3,Phase 2,Phase 1

Antimetabolites

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Autonomic Agents

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Antimetabolites, Antineoplastic

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Antineoplastic Agents, Alkylating

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Antineoplastic Agents, Hormonal

Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable

Prednisolone acetate

Phase 4,Phase 2,Phase 1,Not Applicable

Methylprednisolone acetate

Phase 4,Phase 2,Phase 1,Not Applicable

Methylprednisolone Hemisuccinate

Phase 4,Phase 2,Phase 1,Not Applicable

Neuroprotective Agents

Phase 4,Phase 2,Phase 1,Not Applicable

Angiogenesis Inhibitors

Phase 4,Phase 1,Phase 2

Interventional clinical trials:

(show top 50) (show all 476)

#	Name	Status	NCT ID	Phase	Drugs
1	Bone Marrow Transplantation in Treating Patients With Hematologic Cancer	Completed	NCT00003398	Phase 4	cyclophosphamide;thiotepa
2	The Comparison of RCD Versus BCD in Newly Diagnosed Waldenström Macroglobulinemia	Recruiting	NCT02844322	Phase 4	Bortezomib;Rituximab
3	Comparison of ASCT and Conventional Chemotherapy in High Risk Waldenström Macroglobulinemia	Recruiting	NCT02844361	Phase 4
4	The Efficacy of TCD Following by TP Maintenance Therapy in Newly Diagnosed WM	Recruiting	NCT02844309	Phase 4	Thalidomide
5	Rituximab (RTX) Therapy in Patients With Active TAO	Recruiting	NCT02378298	Phase 4	Rituximab;Iv Methylprednisolone;peroral methylprednisolone and Methotrexate
6	Interferon Alfa-2b Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Hodgkin's Disease or Non-Hodgkin's Lymphoma	Unknown status	NCT00003924	Phase 3
7	Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain	Unknown status	NCT01316744	Phase 3	ketamine hydrochloride
8	Early Hospital Discharge or Standard Inpatient Care in Cancer Patients Receiving Antibiotics for Febrile Neutropenia	Unknown status	NCT00445497	Phase 3	amoxicillin-clavulanate potassium;ciprofloxacin
9	Trial Comparing Chlorambucil to Fludarabine in Patients With Advanced Waldenström Macroglobulinemia	Completed	NCT00566332	Phase 3	Chlorambucil;Fludarabine
10	Chlorambucil or Fludarabine as First-Line Therapy in Treating Patients With Previously Untreated Waldenström Macroglobulinemia, Splenic Lymphoma, or Lymphoplasmacytic Lymphoma	Completed	NCT00608374	Phase 3	chlorambucil;fludarabine phosphate
11	A Study Comparing Maintenance Subcutaneous Rituximab With Observation Only in Participants With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma Who Had Responded to Rituximab-based Immunochemotherapy Induction and 2-year Maintenance With Subcutaneo	Completed	NCT01461928	Phase 3	Chemotherapy (Induction Period);Rituximab
12	Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant	Completed	NCT01231412	Phase 3	Cyclosporine;Fludarabine Phosphate;Mycophenolate Mofetil;Sirolimus
13	Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer	Completed	NCT00075478	Phase 3	Fludarabine Phosphate;Mycophenolate Mofetil;Cyclosporine
14	Radiation Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma Who Have Undergone Stem Cell Transplantation	Completed	NCT00031668	Phase 3
15	Darbepoetin Alfa Compared With Epoetin Alfa in Treating Anemia in Patients Receiving Chemotherapy for Cancer	Completed	NCT00070382	Phase 3	darbepoetin alfa;epoetin alfa
16	Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial	Completed	NCT00750009	Phase 3
17	Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain	Completed	NCT00666211	Phase 3
18	Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer	Completed	NCT00661999	Phase 3	sodium ferric gluconate complex in sucrose
19	American Ginseng in Treating Patients With Fatigue Caused by Cancer	Completed	NCT00719563	Phase 3	American ginseng
20	Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain	Completed	NCT00538850	Phase 3	Fentanyl sublingual spray;Placebo
21	Sibling Donor Peripheral Stem Cell Transplant or Sibling Donor Bone Marrow Transplant in Treating Patients With Hematologic Cancers or Other Diseases	Completed	NCT00438958	Phase 3
22	Prevention of Infection in Patients With Hematologic Cancer and Persistent Fever Caused by a Low White Blood Cell Count	Completed	NCT00003805	Phase 3	piperacillin sodium;piperacillin-tazobactam;tazobactam sodium;vancomycin
23	St. John's Wort in Relieving Fatigue in Patients Undergoing Chemotherapy or Hormone Therapy for Cancer	Completed	NCT00005805	Phase 3
24	Epoetin Alfa in Treating Anemia in Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma and Anemia Caused By Chemotherapy	Completed	NCT00003341	Phase 3
25	Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment	Completed	NCT00006348	Phase 3	ondansetron
26	Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment	Completed	NCT00008359	Phase 3	caspofungin acetate;liposomal amphotericin B
27	Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients	Completed	NCT00003938	Phase 3	liposomal amphotericin B
28	Treatment for Chronic Pain in Patients With Advanced Cancer	Completed	NCT00003687	Phase 3	dextromethorphan hydrobromide;morphine sulfate
29	First-line R-CVP vs R-CHOP Induction Immunochemotherapy for Indolent Lymphoma and R Maintenance.	Completed	NCT00801281	Phase 3	Rituximab;Cyclophosphamide;Doxorubicin;Vincristine;Prednisone 1;Prednisone 2
30	Efficacy of First Line DRC +/- Bortezomib for Patients With Waldenström's Macroglobulinemia	Recruiting	NCT01788020	Phase 3	Dexamethasone, Rituximab, Cyclophosphamide;Dexamethasone, Rituximab, Cyclophosphamide, Bortezomib
31	Efficacy and Safety of Ibrutinib in Patients With CLL and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus Carriers	Recruiting	NCT02991638	Phase 3	Ibrutinib
32	Ibrutinib With Rituximab in Adults With Waldenström's Macroglobulinemia	Active, not recruiting	NCT02165397	Phase 3	Ibrutinib;Placebo;Rituximab
33	A Study Comparing BGB-3111 and Ibrutinib in Subjects With Waldenström's Macroglobulinemia (WM)	Active, not recruiting	NCT03053440	Phase 3	BGB-3111;Ibrutinib
34	Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer	Active, not recruiting	NCT00003816	Phase 2, Phase 3	busulfan;carboplatin;cyclophosphamide;etoposide;fludarabine phosphate;melphalan;thiotepa
35	Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas	Terminated	NCT01732926	Phase 3	Idelalisib;Rituximab;Bendamustine;Placebo
36	Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas	Terminated	NCT01732913	Phase 3	Placebo;Rituximab;Idelalisib
37	A Study of Belimumab in Treating Symptomatic Waldenstroms Macroglobulinaemia	Unknown status	NCT01142011	Phase 2	Belimumab
38	Bortezomib, Dexamethasone, and Rituximab in Previously Untreated Patients With Waldenstrom's Macroglobulinemia	Unknown status	NCT01046006	Phase 2	Bortezomib, Rituximab, Dexamethasone
39	Beta Alethine in Treating Patients With Waldenstrom's Macroglobulinemia	Unknown status	NCT00041379	Phase 1, Phase 2	beta alethine
40	A Phase II Study of Carfilzomib in Relapsed Waldenström's Macroglobulinemia (WM) IST-CAR-531	Unknown status	NCT01813227	Phase 2	Carfilzomib;Rituximab;Dexamethasone
41	Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas	Unknown status	NCT01805037	Phase 1, Phase 2	brentuximab vedotin
42	Comparison of Fludarabine Plus Total-Body Irradiation With Combination Chemotherapy Followed by Donor Peripheral Stem Cell Transplantation in Treating Patients With Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia	Unknown status	NCT00041288	Phase 2	cyclophosphamide;cyclosporine;fludarabine phosphate;methotrexate;mycophenolate mofetil;tacrolimus
43	Dendritic Cell Vaccine in Treating Patients With Indolent B-Cell Lymphoma or Multiple Myeloma	Unknown status	NCT00937183	Phase 1, Phase 2
44	Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Other B-cell Cancers	Unknown status	NCT00003163	Phase 2	cyclophosphamide;melphalan
45	Rituximab, Fludarabine, Cyclophosphamide, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed B-Cell Non-Hodgkin's Lymphoma	Unknown status	NCT00397800	Phase 1, Phase 2	cyclophosphamide;fludarabine phosphate
46	Valproic Acid in Treating Patients With Previously Treated Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Chronic Lymphocytic Leukemia	Unknown status	NCT01016990	Phase 2	valproic acid
47	Vaccine Therapy and GM-CSF in Treating Patients With CNS Lymphoma	Unknown status	NCT00621036	Phase 2	methotrexate;thiotepa
48	Study of Lenalidomide in Relapse/Refractory Waldenstrom Macroglobulinemia	Completed	NCT02302469	Phase 1, Phase 2	Revlimid
49	Phase 1/2 Dose Escalation Study in Patients With Relapsed or Refractory Waldenstrom's Macroglobulinemia	Completed	NCT02092909	Phase 1, Phase 2	IMO-8400
50	Efficacy of Bortezomib (Velcade(R)) in Patients With Advanced Waldenström Macroglobulinemia	Completed	NCT00777738	Phase 2	BORTEZOMIB

Search NIH Clinical Center for Macroglobulinemia

Inferred drug relations via UMLS ⁷³ / NDF-RT ⁵¹ :

chlorambucil

cyclophosphamide

ibrutinib

thalidomide

Sources

Genetic Tests for Macroglobulinemia

Sources

Anatomical Context for Macroglobulinemia

MalaCards organs/tissues related to Macroglobulinemia:

⁴¹

B Cells, Bone, Bone Marrow, Liver, T Cells, Kidney, Spleen

Sources

Publications for Macroglobulinemia

Articles related to Macroglobulinemia:

(show top 50) (show all 858)

#	Title	Authors	Year
1	A head-to-head Phase III study comparing zanubrutinib versus ibrutinib in patients with WaldenstrAPm macroglobulinemia. ( 29869556 )	Tam C.S....Buske C.	2018
2	Idelalisib in a patient with refractory WaldenstrAPm's macroglobulinemia complicated by anuric renal failure: a case report. ( 29890999 )	D'Aveni-Piney M....Feugier P.	2018
3	Fifty-Year Incidence of WaldenstrAPm Macroglobulinemia in Olmsted County, Minnesota, From 1961 Through 2010: A Population-Based Study With Complete Case Capture and Hematopathologic Review. ( 29656787 )	Kyle R.A....Rajkumar S.V.	2018
4	Waldenstrom's Macroglobulinemia: An Update. ( 29326801 )	Mazzucchelli M....Tedeschi A.	2018
5	Non-myeloablative allogeneic hematopoietic cell transplantation for relapsed or refractory WaldenstrAPm macroglobulinemia: evidence for a graft-<i>versus</i>-lymphoma effect. ( 29545343 )	Maffini E....Storb R.	2018
6	[<sup>18</sup>F]Florbetaben PET-CT confirms AL amyloidosis in a patient with WaldenstrAPm's Macroglobulinemia. ( 29650640 )	Fox T.A....D'Sa S.	2018
7	Chronic diarrhea: A case of WaldenstrAPm Macroglobulinemia. ( 29463427 )	Amado GarzA^n S.B....Botero BahamA^n J.D.	2018
8	Fitting mSMART Into the Current Clinical Management of WaldenstrAPm Macroglobulinemia. ( 29392274 )	Castillo J.J....Treon S.P.	2018
9	Circulating Soluble Receptor Activator of Nuclear Factor Kappa B Ligand and C-C Motif Ligand 3 Correlate With Survival in Patients With WaldenstrAPm Macroglobulinemia. ( 29685422 )	Eleutherakis-Papaiakovou E....Terpos E.	2018
10	MYD88 mutation status does not impact overall survival in WaldenstrAPm macroglobulinemia. ( 29080258 )	Abeykoon J.P....Kapoor P.	2018
11	A rare neurological complication of Waldenstrom's Macroglobulinemia. ( 29113857 )	Torrealba-Acosta G....Leslie-Mazwi T.	2018
12	Cardiopulmonary Bypass in the Setting of WaldenstrAPm's Macroglobulinemia. ( 29921992 )	D'Aloiso B.D....Rush R.D.	2018
13	Ibrutinib withdrawal symptoms in patients with WaldenstrAPm macroglobulinemia. ( 29472352 )	Castillo J.J....Treon S.P.	2018
14	WaldenstrAPm macroglobulinemia treatment algorithm 2018. ( 29712895 )	Gertz M.A.	2018
15	Waldenstrom macroglobulinemia involving the superior rectus muscle. ( 29780960 )	Hellman J.B....Lin L.K.	2018
16	Imaging spectrum of Bing-Neel syndrome: how can a radiologist recognise this rare neurological complication of WaldenstrAPm's macroglobulinemia? ( 29922935 )	Fitsiori A....Kremer S.	2018
17	A safety profile of medications used to treat WaldenstrAPm's macroglobulinemia. ( 29768934 )	GarcA-a-Sanz R....Sarasquete M.E.	2018
18	Severe hemolysis and transfusion reactions after treatment with BGB-3111 and PD-1 antibody for WaldenstrAPm Macroglobulinemia. ( 29439186 )	Othman J....Gasioroswki R.	2018
19	Chemokine Receptor CXCR4-Targeted PET/CT With 68Ga-Pentixafor Shows Superiority to 18F-FDG in a Patient With WaldenstrAPm Macroglobulinemia. ( 29742593 )	Luo Y....Li F.	2018
20	Impact of ibrutinib dose intensity on patient outcomes in previously treated WaldenstrAPm macroglobulinemia. ( 29773590 )	Castillo J.J....Treon S.P.	2018
21	Kidney Involvement of Patients with WaldenstrAPm Macroglobulinemia and Other IgM-Producing B Cell Lymphoproliferative Disorders. ( 29848505 )	Higgins L....Leung N.	2018
22	Calorimetric markers for monitoring of multiple myeloma and WaldenstrAPm's macroglobulinemia patients. ( 29362827 )	Todinova S....Taneva S.G.	2018
23	WaldenstrAPm macroglobulinemia presenting as cryoglobulinemic type II membranoproliferative glomerulonephritis. ( 29571917 )	AntA^n VA!zquez V....Paredes Henao V.	2018
24	Duodenal Scalloping Diagnoses WaldenstrAPm Macroglobulinemia. ( 29660526 )	Francis F.F....Hashash J.G.	2018
25	Carfilzomib as salvage therapy in Waldenstrom macroglobulinemia: a case series. ( 28583038 )	Vesole D.H....Siegel D.S.	2018
26	Prospective Clinical Trial of Ixazomib, Dexamethasone, and Rituximab as Primary Therapy in WaldenstrAPm Macroglobulinemia. ( 29661775 )	Castillo J.J....Treon S.P.	2018
27	Comparing apples to oranges: A commentary on the Mayo study of MYD88 significance in Waldenstrom's macroglobulinemia. ( 29218718 )	Castillo J.J....Treon S.P.	2018
28	Lung consolidation as a rare presentation of lymphoplasmacytic lymphoma with extramedullary WaldenstrAPm's macroglobulinemia. ( 29686791 )	Abdulfattah O....Schmidt F.	2018
29	Impact of rituximab and half-dose CHOP as primary therapy for untreated symptomatic WaldenstrAPm Macroglobulinemia: review of a combined regimen of rituximab with an alkylating agent. ( 29963517 )	Sekiguchi N....Takezako N.	2018
30	Spotting the elusive Siberian tiger: Complete response to ibrutinib in a patient with WaldenstrAPm Macroglobulinemia. ( 29756293 )	Castillo J.J....Treon S.P.	2018
31	Highly sensitive <i>MYD88</i><sup>L265P</sup> mutation detection by droplet digital polymerase chain reaction in WaldenstrAPm macroglobulinemia. ( 29567768 )	Drandi D....Ferrero S.	2018
32	True, true unrelated? Coexistence of Waldenstrom's macroglobulinemia and cardiac transthyretin Amyloidosis. ( 29674499 )	Singh A....Falk R.H.	2018
33	Intensely Pruritic Papules and Plaques in Waldenstrom's Macroglobulinemia. ( 29386839 )	Lee S....Choi E.H.	2018
34	Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with WaldenstrAPm macroglobulinemia. ( 29610969 )	Paludo J....Kapoor P.	2018
35	Phase 3 Trial of Ibrutinib plus Rituximab in WaldenstrAPm's Macroglobulinemia. ( 29856685 )	Dimopoulos M.A....Buske C.	2018
36	Fitting mSMART Into the Current Clinical Management of WaldenstrAPm Macroglobulinemia-Reply. ( 29392293 )	Kapoor P....Ansell S.M.	2018
37	Current options to manage WaldenstrAPm's macroglobulinemia. ( 28592170 )	Benevolo G....Vitolo U.	2017
38	Dexamethasone, rituximab and cyclophosphamide for relapsedA and/or refractory and treatment-naA^ve patients with Waldenstrom macroglobulinemia. ( 28786474 )	Paludo J....Kapoor P.	2017
39	Normothermic Cardiopulmonary Bypass in Patient With WaldenstrAPm's Macroglobulinemia and Cryoglobulinemia: A Case Report. ( 28520564 )	Satomi S....Tanaka K.	2017
40	Diagnosis and Management of WaldenstrAPm Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines 2016. ( 28056114 )	Kapoor P....Reeder C.B.	2017
41	Retrospective analysis of prognostic factors for WaldenstrOsm macroglobulinemia: a multicenter cooperative study in Japan. ( 28687991 )	Saito A....Tsukamoto N.	2017
42	TP53 Mutation and Its Prognostic Significance in Waldenstrom's Macroglobulinemia. ( 28754818 )	Poulain S....Leleu X.	2017
43	Cutaneous Infiltration due to WaldenstrAPm Macroglobulinemia. ( 28784233 )	Oscoz-Jaime S....Yanguas-Bayona J.I.	2017
44	The importance of the genomic landscape in WaldenstrAPm's Macroglobulinemia for targeted therapeutical interventions. ( 28423722 )	Sacco A....Roccaro A.M.	2017
45	What should be the goal of therapy for WaldenstrAPm macroglobulinemia patients? Complete response should be the goal of therapy. ( 29296899 )	Treon S.P....Castillo J.J.	2017
46	New developments in the management of WaldenstrAPm macroglobulinemia. ( 28331368 )	Abeykoon J.P....Kapoor P.	2017
47	Toward personalized treatment in WaldenstrAPm macroglobulinemia. ( 29222280 )	Castillo J.J....Treon S.P.	2017
48	WaldenstrAPm Macroglobulinemia: Review of Pathogenesis and Management. ( 28366781 )	Yun S....Anwer F.	2017
49	Current treatment options and investigational drugs for Waldenstrom's Macroglobulinemia. ( 28043164 )	Gavriatopoulou M....Dimopoulos M.A.	2017
50	Safety and efficacy of selinexor in relapsed or refractory multiple myeloma and Waldenstrom's macroglobulinemia. ( 29203585 )	Chen C....Reece D.	2017

Sources

Genes for Macroglobulinemia

Genes related to Macroglobulinemia (0 elite genes):

(show all 14)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence
1	MYD88	Myeloid Differentiation Primary Response 88	Protein Coding	43.89	DISEASES inferred ¹⁵ GeneCards inferred via : Disorders Publications Variants (show sections)
2	CD40LG	CD40 Ligand	Protein Coding	26.29	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
3	CXCR4	C-X-C Motif Chemokine Receptor 4	Protein Coding	24.11	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
4	BTK	Bruton Tyrosine Kinase	Protein Coding	23.91	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
5	TNFSF13B	TNF Superfamily Member 13b	Protein Coding	21.7	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
6	PAX5	Paired Box 5	Protein Coding	21.62	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
7	CD27	CD27 Molecule	Protein Coding	21.61	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
8	CD70	CD70 Molecule	Protein Coding	21.37	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
9	AKT1	AKT Serine/Threonine Kinase 1	Protein Coding	21.25	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
10	IL6	Interleukin 6	Protein Coding	21.18	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
11	SLC28A1	Solute Carrier Family 28 Member 1	Protein Coding	21.12	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
12	CXCL12	C-X-C Motif Chemokine Ligand 12	Protein Coding	20.96	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
13	TNFRSF13B	TNF Receptor Superfamily Member 13B	Protein Coding	20.91	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
14	ITGAE	Integrin Subunit Alpha E	Protein Coding	20.87	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)

Sources

Variations for Macroglobulinemia

Sources

Expression for Macroglobulinemia

Search GEO for disease gene expression data for Macroglobulinemia.

Sources

Pathways for Macroglobulinemia

Pathways related to Macroglobulinemia according to GeneCards Suite gene sharing:

(show all 30)

#	Super pathways	Score	Top Affiliating Genes
1	Innate Immune System ⁶⁶ Show member pathways Immune System ⁶⁶ Neutrophil degranulation ⁶⁶	13.89	AKT1 BTK CD27 CD40LG CD70 IL6
2	ERK Signaling ⁶⁴ Show member pathways ILK Signaling ⁶⁴ MAPK Signaling ⁶⁴ Molecular Mechanisms of Cancer ⁶⁴ Rho Family GTPases ⁶⁴	13.64	AKT1 BTK CD27 CD40LG CD70 CXCL12
3	PEDF Induced Signaling ⁶⁴ Show member pathways all-trans-Retinoic Acid Signaling in Brain ⁶⁴ Cytokine-cytokine receptor interaction ³⁷ Endothelin-1 Signaling Pathway ⁶⁴ Glucocorticoid Receptor Signaling ⁶⁴ IL-6 Pathway ⁶⁴ MIF Mediated Glucocorticoid Regulation ⁶⁴ MIF Regulation of Innate Immune Cells ⁶⁴ NFAT Signaling and Lymphocyte Interactions ⁶⁴ PGC1Alpha Pathway ⁶⁴ RAR-Gamma-RXR-Alpha Degradation ⁶⁴ STAT3 Pathway ⁶⁴	13.5	AKT1 BTK CD27 CD40LG CD70 CXCL12
4	TGF-Beta Pathway ⁶⁴ Show member pathways JAK-STAT Pathway ⁶⁴ JNK Pathway ⁶⁴ MAPK Family Pathway ⁶⁴ Regulation of eIF4 and p70S6K ⁶⁴ SOCS Pathway ⁶⁴	13.39	AKT1 BTK CXCL12 CXCR4 IL6 ITGAE
5	Cytokine Signaling in Immune system ⁶⁶ Show member pathways Signaling by Interleukins ⁶⁶	13.22	AKT1 CD27 CD40LG CD70 IL6 MYD88
6	Phospholipase-C Pathway ⁶⁴ Show member pathways PTEN Pathway ⁶⁴	12.93	AKT1 BTK CXCL12 IL6 ITGAE
7	Allograft rejection ¹ ³⁷ Show member pathways Antigen processing and presentation ³⁷ Asthma ³⁷ Autoimmune thyroid disease ³⁷ CTL Mediated Apoptosis ⁶⁴ Graft-versus-host disease ³⁷ Intestinal immune network for IgA production ³⁷ THC Differentiation Pathway ⁶⁴ Type I diabetes mellitus ³⁷ Viral myocarditis ³⁷	12.74	CD40LG CXCL12 CXCR4 IL6 TNFRSF13B TNFSF13B
8	TNFR1 Pathway ⁶⁴ Show member pathways Apoptosis and survival TNFR1 signaling pathway ²² Apoptosis through Death Receptors ⁶⁴ Apoptotic Pathways Triggered By HIV1 ⁶⁴ DR3 Signaling ⁶⁴ Fas Signaling ⁶⁴ GITR Pathway ⁶⁴ HIV-1 Nef- Negative effector of Fas and TNF-alpha ¹ Stimulation of the cell death response by PAK-2p34 ⁶⁶ TNF alpha Signaling Pathway ¹ TNF related weak inducer of apoptosis (TWEAK) Signaling Pathway ¹ TNF Signaling ⁶⁴ TRAIL Pathway ⁶⁴ TWEAK Pathway ⁶⁴	12.73	AKT1 BTK CXCR4 IL6
9	PAK Pathway ⁶⁴ Show member pathways Antioxidant Action of Vitamin-C ⁶⁴ Epithelial Adherens Junctions ⁶⁴	12.72	AKT1 BTK CD27 CD40LG CD70 CXCL12
10	NF-KappaB Family Pathway ⁶⁴ Show member pathways NF-KappaB (p50-p65) Pathway ⁶⁴	12.59	AKT1 CD40LG CXCL12 IL6 MYD88 TNFSF13B
11	Development Angiotensin activation of ERK ²² Show member pathways Cell adhesion Integrin inside-out signaling ²² Development ACM2 and ACM4 activation of ERK ²² Development Angiotensin signaling via PYK2 ²² Development EDNRB signaling ²² Development EPO-induced MAPK pathway ²² Development G-Proteins mediated regulation MARK-ERK signaling ²² Signal transduction IP3 signaling ²²	12.57	AKT1 BTK CD27 CD40LG CD70 CXCL12
12	Akt Signaling ⁶⁴ Show member pathways p38 Signaling ⁶⁴ Tec Kinases Signaling ⁶⁴	12.55	AKT1 BTK CD27 CD40LG CD70 CXCL12
13	4-1BB Pathway ⁶⁴ Show member pathways CD27 Pathway ⁶⁴ CD40 Signaling ⁶⁴ CMV and MAPK Pathways ⁶⁴ NF-KappaB Activation by EBV ⁶⁴ NF-kappaB Activation by Viruses ⁶⁴ PKR Pathway ⁶⁴ SUMO Pathway ⁶⁴ TNFR2 Pathway ⁶⁴	12.54	AKT1 CD27 CD40LG CD70 CXCR4
14	TRAF Pathway ⁶⁴ Show member pathways 14-3-3 Induced Apoptosis ⁶⁴ TNF Superfamily Pathway ⁶⁴ Toll-Like Receptors Pathway ⁶⁴	12.41	AKT1 CD40LG MYD88 TNFRSF13B TNFSF13B
15	NF-kappaB Signaling ⁴	12.38	BTK CD40LG CXCL12 CXCR4 MYD88 PAX5
16	C-type lectin receptor signaling pathway ³⁷ Show member pathways Pathogen or Damage-activated C-Type Lectin Receptor Signaling Pathways ⁶⁵	12.12	AKT1 BTK IL6 MYD88
17	Immune response IFN gamma signaling pathway ²² Show member pathways IFN-gamma pathway ¹	11.99	AKT1 BTK CXCL12 IL6 TNFSF13B
18	Jak-Stat Signaling Pathway ⁶⁷	11.81	AKT1 CXCL12 CXCR4 IL6
19	Rheumatoid arthritis ³⁷	11.76	CXCL12 IL6 TNFSF13B
20	NF-kappa B signaling pathway ³⁷	11.74	BTK CD40LG CXCL12 MYD88 TNFSF13B
21	CXCR4-mediated signaling events ¹	11.68	AKT1 CXCL12 CXCR4
22	Apoptosis and survival Anti-apoptotic TNFs/NF-kB/Bcl-2 pathway ²² Show member pathways Apoptosis and survival Anti-apoptotic TNFs/NF-kB/IAP pathway ²²	11.66	CD40LG TNFRSF13B TNFSF13B
23	HIF-1-alpha transcription factor network ¹	11.61	AKT1 CXCL12 CXCR4
24	T Cell Co-Signaling Pathway: Ligand-Receptor Interactions ⁶⁵	11.54	CD27 CD40LG CD70
25	Malaria ³⁷	11.46	CD40LG IL6 MYD88
26	Thymic Stromal LymphoPoietin (TSLP) Signaling Pathway ¹	11.44	AKT1 BTK IL6
27	B Cell Development Pathways ⁶⁵	11.38	CD27 CD40LG CXCR4 PAX5 TNFRSF13B
28	Primary immunodeficiency ³⁷	11.3	BTK CD40LG TNFRSF13B
29	Syndecan-4-mediated signaling events ¹	11.2	CXCL12 CXCR4 TNFRSF13B
30	TNFs bind their physiological receptors ⁶⁶	11.18	CD27 CD70 TNFRSF13B TNFSF13B

Sources

GO Terms for Macroglobulinemia

Cellular components related to Macroglobulinemia according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	plasma membrane	GO:0005886	9.4	AKT1 BTK CD27 CD40LG CD70 CXCL12
2	external side of plasma membrane	GO:0009897	9.26	CD27 CD40LG CXCL12 ITGAE

Biological processes related to Macroglobulinemia according to GeneCards Suite gene sharing:

(show all 19)

#	Name	GO ID	Score	Top Affiliating Genes
1	apoptotic process	GO:0006915	9.93	AKT1 BTK CD27 CXCR4 MYD88
2	negative regulation of apoptotic process	GO:0043066	9.89	AKT1 CD27 CD40LG IL6 MYD88
3	regulation of signaling receptor activity	GO:0010469	9.77	CD40LG CD70 CXCL12 IL6 TNFSF13B
4	platelet activation	GO:0030168	9.73	AKT1 CD40LG IL6
5	response to virus	GO:0009615	9.72	CXCL12 CXCR4 MYD88
6	T cell costimulation	GO:0031295	9.65	AKT1 CD40LG TNFSF13B
7	immune response	GO:0006955	9.63	CD27 CD40LG CD70 CXCL12 IL6 TNFSF13B
8	positive regulation of T cell proliferation	GO:0042102	9.61	CD40LG IL6 TNFSF13B
9	endocrine pancreas development	GO:0031018	9.58	AKT1 IL6
10	B cell homeostasis	GO:0001782	9.58	TNFRSF13B TNFSF13B
11	positive regulation of smooth muscle cell proliferation	GO:0048661	9.58	AKT1 IL6 MYD88
12	negative regulation of B cell proliferation	GO:0030889	9.57	BTK TNFRSF13B
13	positive regulation of NF-kappaB transcription factor activity	GO:0051092	9.56	BTK CD40LG IL6 MYD88
14	positive regulation of B cell differentiation	GO:0045579	9.52	BTK CD27
15	immunoglobulin mediated immune response	GO:0016064	9.51	CD27 MYD88
16	response to peptidoglycan	GO:0032494	9.46	IL6 MYD88
17	inflammatory response	GO:0006954	9.43	AKT1 CD27 CD40LG CXCR4 IL6 MYD88
18	immunoglobulin secretion	GO:0048305	9.32	CD40LG TNFSF13B
19	tumor necrosis factor-mediated signaling pathway	GO:0033209	9.02	CD27 CD40LG CD70 TNFRSF13B TNFSF13B

Molecular functions related to Macroglobulinemia according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	signaling receptor binding	GO:0005102	9.55	BTK CD70 CXCL12 MYD88 TNFSF13B
2	tumor necrosis factor receptor binding	GO:0005164	9.13	CD40LG CD70 TNFSF13B
3	cytokine activity	GO:0005125	9.02	CD40LG CD70 CXCL12 IL6 TNFSF13B

Sources

Sources for Macroglobulinemia

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ ExPASy

¹⁸ FDA Approved Drugs

¹⁹ FMA

²⁰ GeneAnalytics

²¹ GeneCards

²² GeneGo (Thomson Reuters)

²³ GeneHancer via GeneCards

²⁴ GeneReviews

²⁵ Genetics Home Reference

²⁶ GenomeRNAi

²⁷ GEO DataSets

²⁸ GO

²⁹ GTR

³⁰ HGMD

³¹ HMDB

³² HPO

³³ ICD10

³⁴ ICD10 via Orphanet

³⁵ ICD9CM

³⁶ IUPHAR

³⁷ KEGG

³⁸ LifeMap

³⁹ LncRNADisease

⁴⁰ LOVD

⁴¹ MalaCards

⁴² MedGen

⁴³ MedlinePlus

⁴⁴ MeSH

⁴⁵ MESH via Orphanet

⁴⁶ MGI

⁴⁷ miR2Disease

⁴⁸ NCBI Bookshelf

⁴⁹ NCI

⁵⁰ NCIt

⁵¹ NDF-RT

⁵² NIH Clinical Center

⁵³ NIH Rare Diseases

⁵⁴ NINDS

⁵⁵ Novoseek

⁵⁶ Novus Biologicals

⁵⁷ OMIM

⁵⁸ OMIM via Orphanet

⁵⁹ Orphanet

⁶⁰ PathCards

⁶¹ PharmGKB

⁶² PubMed

⁶³ PubMed Health

⁶⁴ QIAGEN

⁶⁵ R&D Systems

⁶⁶ Reactome

⁶⁷ Sino Biological

⁶⁸ SNOMED-CT

⁶⁹ SNOMED-CT via HPO

⁷⁰ SNOMED-CT via Orphanet

⁷¹ TGDB

⁷² Tocris

⁷³ UMLS

⁷⁴ UMLS via Orphanet

⁷⁵ UniProtKB/Swiss-Prot

⁷⁶ Wikipedia

Macroglobulinemia

Aliases & Classifications for Macroglobulinemia

MalaCards integrated aliases for Macroglobulinemia:

Classifications:

External Ids:

Summaries for Macroglobulinemia

Related Diseases for Macroglobulinemia

Diseases related to Macroglobulinemia via text searches within MalaCards or GeneCards Suite gene sharing:

Graphical network of the top 20 diseases related to Macroglobulinemia:

Symptoms & Phenotypes for Macroglobulinemia

GenomeRNAi Phenotypes related to Macroglobulinemia according to GeneCards Suite gene sharing:

MGI Mouse Phenotypes related to Macroglobulinemia:

Drugs & Therapeutics for Macroglobulinemia

Drugs for Macroglobulinemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

Interventional clinical trials:

Inferred drug relations via UMLS 73 / NDF-RT 51 :

Genetic Tests for Macroglobulinemia

Anatomical Context for Macroglobulinemia

MalaCards organs/tissues related to Macroglobulinemia:

Publications for Macroglobulinemia

Articles related to Macroglobulinemia:

Genes for Macroglobulinemia

Genes related to Macroglobulinemia (0 elite genes):

Variations for Macroglobulinemia

Expression for Macroglobulinemia

Pathways for Macroglobulinemia

Pathways related to Macroglobulinemia according to GeneCards Suite gene sharing:

GO Terms for Macroglobulinemia

Cellular components related to Macroglobulinemia according to GeneCards Suite gene sharing:

Biological processes related to Macroglobulinemia according to GeneCards Suite gene sharing:

Molecular functions related to Macroglobulinemia according to GeneCards Suite gene sharing:

Sources for Macroglobulinemia

Inferred drug relations via UMLS ⁷³ / NDF-RT ⁵¹ :